Mirjam Johnson-Blattner

Heidelberg, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Primary mismatch repair deficient glioma, IDH-wildtype and H3-wildtype: A giant cell tumor with potential for long-term survival occurring at all ages.

Primary mismatch repair deficient glioma, IDH-wildtype and H3-wildtype: A giant cell tumor with potential for long-term survival occurring at all ages.

Journal: Neuro-oncology

Published: December 15, 2025

Primary Mismatch Repair Deficient Glioma (PMMRDG), IDH-wildtype and H3-wildtype: A Giant Cell Tumor with Potential for Long-Term Survival Occurring at all Ages.

Primary Mismatch Repair Deficient Glioma (PMMRDG), IDH-wildtype and H3-wildtype: A Giant Cell Tumor with Potential for Long-Term Survival Occurring at all Ages.

Journal: Neuro-oncology

Published: December 15, 2025

Integration and validation of complementary ex vivo assays for functional precision oncology.

Integration and validation of complementary ex vivo assays for functional precision oncology.

Journal: NPJ precision oncology

Published: October 30, 2025

Molecular characterization and clinical features of diffuse midline glioma in the pediatric precision oncology registry INFORM.

Molecular characterization and clinical features of diffuse midline glioma in the pediatric precision oncology registry INFORM.

Journal: Acta neuropathologica

Published: May 29, 2025

Advancing CNS tumor diagnostics with expanded DNA methylation-based classification.

Advancing CNS tumor diagnostics with expanded DNA methylation-based classification.

Journal: Cancer cell

Published: May 06, 2025

Corrigendum to "Implementation of paediatric precision oncology into clinical practice: The individualized therapies for children with cancer program 'iTHER'" [Eur J Cancer 175 (2022) 311-325].

Corrigendum to "Implementation of paediatric precision oncology into clinical practice: The individualized therapies for children with cancer program 'iTHER'" [Eur J Cancer 175 (2022) 311-325].

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 13, 2025

Germline analysis of an international cohort of pediatric diffuse midline glioma patients.

Germline analysis of an international cohort of pediatric diffuse midline glioma patients.

Journal: Neuro-oncology

Published: March 12, 2025

Pediatric spinal high-grade glioma in the pediatric precision oncology registry INFORM: Identification of potential therapeutic targets.

Pediatric spinal high-grade glioma in the pediatric precision oncology registry INFORM: Identification of potential therapeutic targets.

Journal: Neuro-oncology advances

Published: February 03, 2025

MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade glioma.

MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade glioma.

Journal: Acta neuropathologica

Published: November 13, 2024

Integrative Multiomics and Drug Sensitivity Profiling Reveal Potential Biomarkers and Therapeutic Strategies in Pediatric Solid Tumors.

Integrative Multiomics and Drug Sensitivity Profiling Reveal Potential Biomarkers and Therapeutic Strategies in Pediatric Solid Tumors.

Journal: Cancer research

Published: June 16, 2024

Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile.

Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile.

Journal: Neuro-oncology

Published: May 08, 2024

Oncogene aberrations drive medulloblastoma progression, not initiation.

Oncogene aberrations drive medulloblastoma progression, not initiation.

Journal: Nature

Published: January 03, 2024

Showing 1-12 of 32

Last Updated: 09/26/2026